{"id":1896,"date":"2010-10-01T01:00:00","date_gmt":"2010-10-01T00:00:00","guid":{"rendered":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/"},"modified":"2018-10-20T18:39:55","modified_gmt":"2018-10-20T16:39:55","slug":"bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique","status":"publish","type":"post","link":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/","title":{"rendered":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique."},"content":{"rendered":"<p><strong>2010<\/strong><\/p>\n<p><em>L.Legros,D.Grasset, C.Vernet, A.Fichet, V.Bicheler, D.Rio,A Ulvoas, J.Gavard, JF.Bouret. Centre hospitalier Bretagne Atlantique, 56000 Vannes.<\/em><\/p>\n<p><strong>Gastroent\u00e9rologie <\/strong>&#8211; \u00a02010-09-03 &#8211;\u00a0CO &#8211;<\/p>\n<p>________________________________<\/p>\n<p>Le Bevacizumab est un anticorps monoclonal humanis\u00e9 anti-VEGF utilis\u00e9 dans le traitement des cancers du fait de son r\u00f4le antiangiog\u00e8nique. Dans le cancer du colon m\u00e9tastatique, il est indiqu\u00e9 en traitement de premi\u00e8re ou deuxi\u00e8me ligne en association \u00e0 la chimioth\u00e9rapie.<br \/>\nIl s\u2019agit d\u2019un traitement bien tol\u00e9r\u00e9 dont la toxicit\u00e9 vasculaire est bien codifi\u00e9e (prot\u00e9inurie, HTA). La survenue d\u2019une perforation intestinale est une complication rare (2%) mais grave (mortalit\u00e9 de 20 \u00e0 30 %) de ce traitement.<br \/>\nNous rapportons 3 cas de perforation colique survenus depuis 2006 dans notre unit\u00e9 en cours de chimioth\u00e9rapie (Folfiri) associ\u00e9e \u00e0 de l\u2019Avastin (5 mg\/kg). Ces 3 observations (sur un total de 55 patients ayant re\u00e7u de l\u2019Avastin durant cette p\u00e9riode dans notre centre hospitalier) ont en commun : la pr\u00e9sence d\u2019une carcinose p\u00e9riton\u00e9ale \u00ab floride \u00bb avec masses abdominales palpables, la survenue pr\u00e9coce au cours des 3 premiers mois d\u2019Avastin, une  colectomie pour le traitement de la tumeur primitive 1 \u00e0 3 ans auparavant, il s\u2019agissait de patientes \u00e2g\u00e9es de 50 \u00e0 70 ans. L\u2019\u00e9volution a \u00e9t\u00e9 fatale dans 2 cas (J5 et J30).<br \/>\nLes facteurs de risque de perforation intestinale sous Avastin sont : cancer colique en place, diverticulite, occlusion, ulc\u00e8re gastroduod\u00e9nal, carcinose p\u00e9riton\u00e9ale, polypectomie et proth\u00e8se colique. Le traitement doit \u00eatre conservateur compte tenu notamment du risque de trouble de la cicatrisation li\u00e9 \u00e0 ce produit (d\u00e9lais minimum de 4 semaines recommand\u00e9 avant ou apr\u00e8s une chirurgie). Parmi nos 3 observations, 2 patientes ont d\u00fb \u00eatre op\u00e9r\u00e9es du fait de la gravit\u00e9 du tableau p\u00e9riton\u00e9al et septique.<br \/>\nEn conclusion, la survenue d\u2019une perforation colique sous Bevacizumab (Avastin) est une complication de pronostique sombre en cas de carcinose p\u00e9riton\u00e9ale avec masses palpables au cours de l\u2019\u00e9volution d\u2019un cancer du colon op\u00e9r\u00e9, ce qui doit rendre son utilisation limit\u00e9e dans cette situation.  <\/p>\n<p>Saif MW et al ; Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann. Surg. Oncol. 2007.<br \/>\nBadgwdell MW et al; Management of bevacizumab-associated bowel perforation : a case series and review of the literature Ann. Oncol. 2008; 19 : 577-582.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2010 L.Legros,D.Grasset, C.Vernet, A.Fichet, V.Bicheler, D.Rio,A Ulvoas, J.Gavard, JF.Bouret. Centre hospitalier Bretagne Atlantique, 56000 Vannes. Gastroent\u00e9rologie &#8211; \u00a02010-09-03 &#8211;\u00a0CO &#8211; ________________________________ Le Bevacizumab est un anticorps monoclonal humanis\u00e9 anti-VEGF utilis\u00e9 dans le traitement des cancers du fait de son r\u00f4le antiangiog\u00e8nique. Dans le cancer du colon m\u00e9tastatique, il est indiqu\u00e9 en traitement de premi\u00e8re ou [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[21],"class_list":["post-1896","post","type-post","status-publish","format-standard","hentry","category-gastroenterologie","tag-21"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH<\/title>\n<meta name=\"description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"og:description\" content=\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\" \/>\n<meta property=\"og:site_name\" content=\"Abstracts des congr\u00e8s de l&#039;ANGH\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\" \/>\n<meta property=\"article:published_time\" content=\"2010-10-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-10-20T16:39:55+00:00\" \/>\n<meta name=\"author\" content=\"abstracts\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"abstracts\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\"},\"author\":{\"name\":\"abstracts\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\"},\"headline\":\"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique.\",\"datePublished\":\"2010-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"keywords\":[\"2010\"],\"articleSection\":[\"Gastroenterologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\",\"url\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\",\"name\":\"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH\",\"isPartOf\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#website\"},\"datePublished\":\"2010-10-01T00:00:00+00:00\",\"dateModified\":\"2018-10-20T16:39:55+00:00\",\"description\":\"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study\",\"breadcrumb\":{\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/angh.net\/abstracts\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/angh.net\/abstracts\/#website\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"name\":\"Abstracts des congr\u00e8s de l&#039;ANGH\",\"description\":\"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003\",\"publisher\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/angh.net\/abstracts\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/angh.net\/abstracts\/#organization\",\"name\":\"ANGH\",\"url\":\"https:\/\/angh.net\/abstracts\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"contentUrl\":\"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg\",\"width\":48,\"height\":18,\"caption\":\"ANGH\"},\"image\":{\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ANGH-2136322560030484\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1\",\"name\":\"abstracts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g\",\"caption\":\"abstracts\"},\"url\":\"https:\/\/angh.net\/abstracts\/author\/abstracts\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/","og_locale":"fr_FR","og_type":"article","og_title":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH","og_description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","og_url":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/","og_site_name":"Abstracts des congr\u00e8s de l&#039;ANGH","article_publisher":"https:\/\/www.facebook.com\/ANGH-2136322560030484\/","article_published_time":"2010-10-01T00:00:00+00:00","article_modified_time":"2018-10-20T16:39:55+00:00","author":"abstracts","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"abstracts","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#article","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/"},"author":{"name":"abstracts","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1"},"headline":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique.","datePublished":"2010-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:55+00:00","mainEntityOfPage":{"@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"keywords":["2010"],"articleSection":["Gastroenterologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/","url":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/","name":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique. - Abstracts des congr\u00e8s de l&#039;ANGH","isPartOf":{"@id":"https:\/\/angh.net\/abstracts\/#website"},"datePublished":"2010-10-01T00:00:00+00:00","dateModified":"2018-10-20T16:39:55+00:00","description":"ANGH R\u00e9sum\u00e9s congr\u00e8s H\u00e9patologie Gastroent\u00e9romogie Hepatology Gastroenterology Etudes cliniques Clinical study","breadcrumb":{"@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/angh.net\/abstracts\/bevacizumab-avastin-et-perforation-colique-3-cas-survenus-chez-des-patients-porteurs-dune-carcinose-peritoneale-dorigine-colique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/angh.net\/abstracts\/"},{"@type":"ListItem","position":2,"name":"Bevacizumab (Avastin \u00b0) et perforation colique : 3 cas survenus chez des patients porteurs d\u2019une carcinose p\u00e9riton\u00e9ale d\u2019origine colique."}]},{"@type":"WebSite","@id":"https:\/\/angh.net\/abstracts\/#website","url":"https:\/\/angh.net\/abstracts\/","name":"Abstracts des congr\u00e8s de l&#039;ANGH","description":"Base de donn\u00e9es des abstracts du congr\u00e8s depuis 2003","publisher":{"@id":"https:\/\/angh.net\/abstracts\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/angh.net\/abstracts\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/angh.net\/abstracts\/#organization","name":"ANGH","url":"https:\/\/angh.net\/abstracts\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/","url":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","contentUrl":"https:\/\/angh.net\/abstracts\/wp-content\/uploads\/sites\/2\/2018\/10\/logo_angh_2018_-48px.jpg","width":48,"height":18,"caption":"ANGH"},"image":{"@id":"https:\/\/angh.net\/abstracts\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ANGH-2136322560030484\/"]},{"@type":"Person","@id":"https:\/\/angh.net\/abstracts\/#\/schema\/person\/f532083854369dca4b9f509cfbad90e1","name":"abstracts","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2bb25d9cedd377e33f0ebc4fb5994a2f9d3e02f897704acdcc173c15b7c75253?s=96&d=mm&r=g","caption":"abstracts"},"url":"https:\/\/angh.net\/abstracts\/author\/abstracts\/"}]}},"_links":{"self":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/comments?post=1896"}],"version-history":[{"count":0,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/posts\/1896\/revisions"}],"wp:attachment":[{"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/media?parent=1896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/categories?post=1896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/angh.net\/abstracts\/wp-json\/wp\/v2\/tags?post=1896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}